KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Short term Debt (2016 - 2025)

Gilead Sciences' Short term Debt history spans 17 years, with the latest figure at $2.8 billion for Q4 2025.

  • For Q4 2025, Short term Debt rose 54.66% year-over-year to $2.8 billion; the TTM value through Dec 2025 reached $2.8 billion, up 54.66%, while the annual FY2025 figure was $2.8 billion, 54.66% up from the prior year.
  • Short term Debt reached $2.8 billion in Q4 2025 per GILD's latest filing, roughly flat from $2.8 billion in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $4.0 billion in Q2 2023 to a low of $1.0 billion in Q2 2022.
  • Average Short term Debt over 5 years is $2.3 billion, with a median of $2.3 billion recorded in 2021.
  • Peak YoY movement for Short term Debt: soared 295.4% in 2023, then plummeted 55.16% in 2024.
  • A 5-year view of Short term Debt shows it stood at $1.5 billion in 2021, then skyrocketed by 49.93% to $2.3 billion in 2022, then fell by 20.9% to $1.8 billion in 2023, then rose by 0.95% to $1.8 billion in 2024, then soared by 54.66% to $2.8 billion in 2025.
  • Per Business Quant, the three most recent readings for GILD's Short term Debt are $2.8 billion (Q4 2025), $2.8 billion (Q3 2025), and $2.8 billion (Q2 2025).